PORTON PHARMA SOLUTIONS LTD., a world leading CDMO (Hereafter PORTON) announces plans to invest into a new state of the Art cGMP/API facility inside, Life Science Park Mengeš, Slovenia currently owned and operated by Lek Pharmaceuticals d.d., part of NOVARTIS …
Porton is excited to announce construction of a new, state-of-the-art Crystallization and Drug Product facility in Cranbury, NJ. The new building is projected to open in Q4 of 2022. This facility will be cGMP capable for Drug Product supplies, and …
We are very excited to announce the technical program of Pharma Crystallization Summit 2022. This year’s Summit is in-person only and the seats are limited. We cordially invite CMC leaders/managers of drug development programs, API crystallization experts or solution …
BASKING RIDGE, N.J., June 07, 2022 (GLOBE NEWSWIRE) — MetasTx LLC is driven to create novel therapeutics to treat and prevent metastasis of cancers. Harvey Homan, CEO and Co-Founder has successfully presented at Keiretsu Forum Mid-Atlantic and South East, the …
J-STAR Research is pleased to announce our collaboration in the 3rd Edition of Fundamentals of Solid Formulation (FSF2022) webinar series, featuring an impressive line-up of speakers and topics.
This is a 4-week webinar series with a webinar every Wednesday from …
Expand small and medium-scale CDMO production capacity
March 10th, 2022, Shanghai · China – Porton Pharma Solutions Ltd. announced that it is to acquire 100% equity of China Gateway Pharmaceutical Development Co., Ltd. (referred to as “Gateway Pharmaceutical”), a CDMO …
March 1st, 2022, Chongqing · China – Porton Pharma Solutions Ltd. announced an investment of 420 million to expand CDMO Production Capacity of Small Molecule API in Porton Pharma (Jiangxi) Co., Ltd. which is mainly engaged in customized production of …
Chongqing China, February 10, 2022–Porton Pharma Solutions Ltd. (Porton) today announced it will expand its API CDMO production capacity with approximately RMB 260 million investment in Changshou site, Chongqing in order to capture growing market demand from our global pharmaceutical …
Chongqing · China: On January 16, 2022, Porton Pharma Solutions Ltd. released the “2021 Annual Performance Forecast”. The company expects that revenue and net profit will continue to maintain strongly growth in the year of 2021.
2021 Annual Performance Forecast…
Subtitle: Enabling Public’s Early Access to Good Medicines
On November 6, 2021, Porton Pharma Solutions Ltd. (hereinafter referred to as Porton, stock code: 300363) and Honeywell (NASDAQ code: HON) held a Signing Ceremony of Strategic Cooperation Agreement at the 4th …
J-STAR Research’s subject matter experts are presenting at 2021 AAPS PharmSci360, in Philadelphia, PA, on October 17-20. Our synergistically integrated DS-DP team will discuss the enabling technologies and unique capabilities at J-STAR for debottlenecking drug substance (DS) and drug product …